The Experts below are selected from a list of 258 Experts worldwide ranked by ideXlab platform
Stephen Porter - One of the best experts on this subject based on the ideXlab platform.
-
development and validation of a short version of chronic Oral Mucosal Disease questionnaire comdq 15
Journal of Oral Pathology & Medicine, 2020Co-Authors: Stephen Porter, Paswach Wiriyakijja, S Fedele, T A Hodgson, Roddy Mcmillan, Martina Shephard, Richeal Ni RiordainAbstract:BACKGROUND: The adoption of the Chronic Oral Mucosal Disease Questionnaire (COMDQ) into clinical practice has been low, despite its rigorous development process. A potential limitation of the COMDQ is the high response burden to patients. Therefore, the aim of the present study was to develop and validate a short version of the 26-item COMDQ. METHODS: The COMDQ data of 520 patients with chronic Oral Mucosal Diseases were randomly divided into two subsamples. Descriptive item analysis and exploratory factor analysis (EFA) were performed using data from the first subsample for item reduction and development of the shortened COMDQ. The resulting short version was then validated using confirmatory factor analysis (CFA) on the other subsample. Internal consistency reliability of the short-form COMDQ was assessed using Cronbach's alpha. Criterion validity of this new scale was examined against its original version. RESULTS: Based upon item analysis, 11 items were dropped. EFA results on the remaining 15 items extracted four factors consistent with the original COMDQ, and CFA results displayed acceptable goodness-of-fit indices of this factor structure on different sample. The COMDQ-15 was then created. Cronbach's alpha of four subscale scores ranged from 0.7 to 0.91, indicating good internal consistency reliability of the COMDQ-15. Correlations between total and subscale scores of the COMDQ-15 and its parent scale were high, supporting good criterion validity of this shortened scale. CONCLUSION: The COMDQ-15 is a brief, valid and reliable instrument that can give an overview of the patient's quality of life related to their chronic Oral Mucosal conditions.
-
Development and validation of a short version of Chronic Oral Mucosal Disease Questionnaire (COMDQ‐15)
Journal of Oral Pathology & Medicine, 2019Co-Authors: Paswach Wiriyakijja, Stephen Porter, S Fedele, T A Hodgson, Roddy Mcmillan, Martina Shephard, Richeal Ni RiordainAbstract:BACKGROUND: The adoption of the Chronic Oral Mucosal Disease Questionnaire (COMDQ) into clinical practice has been low, despite its rigorous development process. A potential limitation of the COMDQ is the high response burden to patients. Therefore, the aim of the present study was to develop and validate a short version of the 26-item COMDQ. METHODS: The COMDQ data of 520 patients with chronic Oral Mucosal Diseases were randomly divided into two subsamples. Descriptive item analysis and exploratory factor analysis (EFA) were performed using data from the first subsample for item reduction and development of the shortened COMDQ. The resulting short version was then validated using confirmatory factor analysis (CFA) on the other subsample. Internal consistency reliability of the short-form COMDQ was assessed using Cronbach's alpha. Criterion validity of this new scale was examined against its original version. RESULTS: Based upon item analysis, 11 items were dropped. EFA results on the remaining 15 items extracted four factors consistent with the original COMDQ, and CFA results displayed acceptable goodness-of-fit indices of this factor structure on different sample. The COMDQ-15 was then created. Cronbach's alpha of four subscale scores ranged from 0.7 to 0.91, indicating good internal consistency reliability of the COMDQ-15. Correlations between total and subscale scores of the COMDQ-15 and its parent scale were high, supporting good criterion validity of this shortened scale. CONCLUSION: The COMDQ-15 is a brief, valid and reliable instrument that can give an overview of the patient's quality of life related to their chronic Oral Mucosal conditions.
-
Validity and reliability of the Chronic Oral Mucosal Diseases Questionnaire in a UK population.
Journal of Oral Pathology & Medicine, 2016Co-Authors: Richeal Ni Riordain, Tim Hodgson, Stephen Porter, S FedeleAbstract:OBJECTIVE: The objective of this study was to investigate the validity and reliability of a the Chronic Oral Mucosal Diseases Questionnaire in a UK population METHODS: Two hundred patients with chronic Oral Mucosal Disease (Oral lichen planus, recurrent aphthous stomatitis, mucous membrane pemphigoid, pemphigus vulgaris) were enrolled in this study from the Oral Medicine Department of University College London Hospitals Trust (UCLHT) Eastman Dental Hospital. Individuals were interviewed using Oral Health Impact Profile (OHIP-14), Visual Analogue Scale (VAS) and Chronic Oral Mucosal Diseases Questionnaire (COMDQ), and the construct validity and internal reliability were examined. RESULTS: Of the 200 study participants, 100 respondents had Oral lichen planus, 42 had recurrent aphthous stomatitis and 58 had vesiculobullous conditions (mucous membrane pemphigoid or pemphigus vulgaris). With regard to construct validity, a moderate to good degree of convergent validity was found between OHIP-14 and VAS and most subscales and the total COMDQ score except the patient support subscale of COMDQ (0.21-0.37). CONCLUSION: COMDQ is a valid and reliable patient-reported outcome measure for patients with chronic Oral Mucosal Diseases in a UK population. It can be considered a valuable instrument in both clinical practice and in Oral medicine research.
-
Common Oral Mucosal Diseases, systemic inflammation, and cardiovascular Diseases in a large cross-sectional US survey
American Heart Journal, 2011Co-Authors: S Fedele, Stephen Porter, Wael Sabbah, Nikos Donos, Francesco D'aiutoAbstract:Background Inflammation of the gingivae (periodontitis) has been associated with raised serum biomarkers of inflammation, sub-clinical markers of atherosclerosis, and increased risk of and/or mortality from cardiovascular Disease (CVD). There remain little information regarding the association between other common Oral inflammatory Disease, systemic inflammation, and CVD. The objective of the study was to assess the association between common Oral Mucosal Diseases, circulating markers of inflammation, and increased prevalence of CVD in a cross-sectional survey of a nationally representative sample of the noninstitutionalized civilians in the United States. Methods Data for this study are from 17,223 men and women aged ≥17 years who received Oral examination as part of the Third National Health and Nutrition Examination Survey. The primary and secondary outcome measures were the association of Oral Mucosal Diseases with raised serum levels of C-reactive protein/fibrinogen and increased prevalence of CVD, respectively. Adjustment for common confounding factors was performed. Results Having Oral Mucosal Disease was associated with systemic inflammation (serum levels of C-reactive protein ≥10 mg/dL) (odds ratio 1.41, 95% CI 1.02-1.94). Individuals with Oral Mucosal Disease were 1.36 times (95% CI 1.02-1.80) more likely to have history of myocardial infarction and 1.33 times (95% CI 1.03-1.71) more likely to report angina than unaffected individuals. All associations were independent of common confounding factors. Conclusions This is the first study to suggest that common Oral Mucosal Diseases are independently associated with raised markers of systemic inflammation and history of CVD.
-
Calcineurin inhibitors in Oral medicine.
Journal of The American Academy of Dermatology, 2009Co-Authors: Khalid A. Al Johani, Stephen Porter, Anne M. Hegarty, S FedeleAbstract:Topically applied calcineurin inhibitors have been suggested to be of some benefit in the treatment of immunologically mediated Oral Mucosal disorders, particularly Oral lichen planus. This article reviews the current evidence of the efficacy and safety of topical calcineurin inhibitor agents in the management of different Oral conditions. Current evidence suggests that topical tacrolimus and pimecrolimus may be of benefit (at least in the short term) in the treatment of immunologically mediated Oral Mucosal Disease, especially Oral lichen planus that has not responded to topical corticosteroids. Both tacrolimus and pimecrolimus are minimally absorbed through the Oral mucosa and give rise to few clinically significant local or systemic adverse side effects. There is little evidence to indicate that topical cyclosporine is more effective than topical corticosteroids for the treatment of immunologically mediated Oral Mucosal Disease. Currently, there is no objective evidence suggesting that topical tacrolimus or pimecrolimus increase the risk of Oral malignancy associated with Oral lichen planus. There is a need for well-designed randomized controlled trials to establish the precise efficacy of topical calcineurin inhibitors for the treatment of immunologically mediated Oral Mucosal Disease.
C Scully - One of the best experts on this subject based on the ideXlab platform.
-
vesiculo erosive Oral Mucosal Disease management with topical corticosteroids 2 protocols monitoring of effects and adverse reactions and the future
Journal of Dental Research, 2005Co-Authors: M A Gonzalezmoles, C ScullyAbstract:Although topical corticosteroids (TCs) are the most widely used drugs in Oral medicine, and specifically in the treatment of vesiculo-erosive Oral Mucosal Disease, there are few evidence-based data for the correct use of these drugs. In this review, we outline the most widely used protocols, the most common reasons for treatment failure, and the adverse effects documented in the literature.
-
Vesiculo-erosive Oral Mucosal Disease—Management with Topical Corticosteroids: (2) Protocols, Monitoring of Effects and Adverse Reactions, and the Future
Journal of Dental Research, 2005Co-Authors: M.a. González-moles, C ScullyAbstract:Although topical corticosteroids (TCs) are the most widely used drugs in Oral medicine, and specifically in the treatment of vesiculo-erosive Oral Mucosal Disease, there are few evidence-based data for the correct use of these drugs. In this review, we outline the most widely used protocols, the most common reasons for treatment failure, and the adverse effects documented in the literature.
-
Oral Mucosal Disease a decade of new entities aetiologies and associations
International Dental Journal, 1994Co-Authors: C ScullyAbstract:: New patterns of Oral Mucosal Disease and indeed new disorders have been emerging over the past decade. Although infection with human immunodeficiency viruses (HIV) is having the most profound impact, there are also major changes in Oral health and the standard of health care required, because of other new disorders and medical care. The increase in tissue transplantation, with the concomitant use of immunosuppression is resulting in a range of Oral problems. Other iatrogenic Oral Diseases likely to increase include ulcers associated with cytotoxic chemotherapy; lichenoid eruptions related to drugs and restorative materials; and a multiplicity of other complications. Dilemmas are presented by some new disorders such as orofacial granulomatosis. No less are the difficulties presented by the now obvious heterogeneous nature of Oral subepithelial vesiculobullous disorders. Finally, there are, even in these days of social medicine and antimicrobial availability, new infectious Diseases emerging. Continued increases in population mobility; continued sexual promiscuity; and the development of new drugs are all likely to act to increase the spectrum of Oral disorders seen.
S Fedele - One of the best experts on this subject based on the ideXlab platform.
-
development and validation of a short version of chronic Oral Mucosal Disease questionnaire comdq 15
Journal of Oral Pathology & Medicine, 2020Co-Authors: Stephen Porter, Paswach Wiriyakijja, S Fedele, T A Hodgson, Roddy Mcmillan, Martina Shephard, Richeal Ni RiordainAbstract:BACKGROUND: The adoption of the Chronic Oral Mucosal Disease Questionnaire (COMDQ) into clinical practice has been low, despite its rigorous development process. A potential limitation of the COMDQ is the high response burden to patients. Therefore, the aim of the present study was to develop and validate a short version of the 26-item COMDQ. METHODS: The COMDQ data of 520 patients with chronic Oral Mucosal Diseases were randomly divided into two subsamples. Descriptive item analysis and exploratory factor analysis (EFA) were performed using data from the first subsample for item reduction and development of the shortened COMDQ. The resulting short version was then validated using confirmatory factor analysis (CFA) on the other subsample. Internal consistency reliability of the short-form COMDQ was assessed using Cronbach's alpha. Criterion validity of this new scale was examined against its original version. RESULTS: Based upon item analysis, 11 items were dropped. EFA results on the remaining 15 items extracted four factors consistent with the original COMDQ, and CFA results displayed acceptable goodness-of-fit indices of this factor structure on different sample. The COMDQ-15 was then created. Cronbach's alpha of four subscale scores ranged from 0.7 to 0.91, indicating good internal consistency reliability of the COMDQ-15. Correlations between total and subscale scores of the COMDQ-15 and its parent scale were high, supporting good criterion validity of this shortened scale. CONCLUSION: The COMDQ-15 is a brief, valid and reliable instrument that can give an overview of the patient's quality of life related to their chronic Oral Mucosal conditions.
-
Development and validation of a short version of Chronic Oral Mucosal Disease Questionnaire (COMDQ‐15)
Journal of Oral Pathology & Medicine, 2019Co-Authors: Paswach Wiriyakijja, Stephen Porter, S Fedele, T A Hodgson, Roddy Mcmillan, Martina Shephard, Richeal Ni RiordainAbstract:BACKGROUND: The adoption of the Chronic Oral Mucosal Disease Questionnaire (COMDQ) into clinical practice has been low, despite its rigorous development process. A potential limitation of the COMDQ is the high response burden to patients. Therefore, the aim of the present study was to develop and validate a short version of the 26-item COMDQ. METHODS: The COMDQ data of 520 patients with chronic Oral Mucosal Diseases were randomly divided into two subsamples. Descriptive item analysis and exploratory factor analysis (EFA) were performed using data from the first subsample for item reduction and development of the shortened COMDQ. The resulting short version was then validated using confirmatory factor analysis (CFA) on the other subsample. Internal consistency reliability of the short-form COMDQ was assessed using Cronbach's alpha. Criterion validity of this new scale was examined against its original version. RESULTS: Based upon item analysis, 11 items were dropped. EFA results on the remaining 15 items extracted four factors consistent with the original COMDQ, and CFA results displayed acceptable goodness-of-fit indices of this factor structure on different sample. The COMDQ-15 was then created. Cronbach's alpha of four subscale scores ranged from 0.7 to 0.91, indicating good internal consistency reliability of the COMDQ-15. Correlations between total and subscale scores of the COMDQ-15 and its parent scale were high, supporting good criterion validity of this shortened scale. CONCLUSION: The COMDQ-15 is a brief, valid and reliable instrument that can give an overview of the patient's quality of life related to their chronic Oral Mucosal conditions.
-
Validity and reliability of the Chronic Oral Mucosal Diseases Questionnaire in a UK population.
Journal of Oral Pathology & Medicine, 2016Co-Authors: Richeal Ni Riordain, Tim Hodgson, Stephen Porter, S FedeleAbstract:OBJECTIVE: The objective of this study was to investigate the validity and reliability of a the Chronic Oral Mucosal Diseases Questionnaire in a UK population METHODS: Two hundred patients with chronic Oral Mucosal Disease (Oral lichen planus, recurrent aphthous stomatitis, mucous membrane pemphigoid, pemphigus vulgaris) were enrolled in this study from the Oral Medicine Department of University College London Hospitals Trust (UCLHT) Eastman Dental Hospital. Individuals were interviewed using Oral Health Impact Profile (OHIP-14), Visual Analogue Scale (VAS) and Chronic Oral Mucosal Diseases Questionnaire (COMDQ), and the construct validity and internal reliability were examined. RESULTS: Of the 200 study participants, 100 respondents had Oral lichen planus, 42 had recurrent aphthous stomatitis and 58 had vesiculobullous conditions (mucous membrane pemphigoid or pemphigus vulgaris). With regard to construct validity, a moderate to good degree of convergent validity was found between OHIP-14 and VAS and most subscales and the total COMDQ score except the patient support subscale of COMDQ (0.21-0.37). CONCLUSION: COMDQ is a valid and reliable patient-reported outcome measure for patients with chronic Oral Mucosal Diseases in a UK population. It can be considered a valuable instrument in both clinical practice and in Oral medicine research.
-
Common Oral Mucosal Diseases, systemic inflammation, and cardiovascular Diseases in a large cross-sectional US survey
American Heart Journal, 2011Co-Authors: S Fedele, Stephen Porter, Wael Sabbah, Nikos Donos, Francesco D'aiutoAbstract:Background Inflammation of the gingivae (periodontitis) has been associated with raised serum biomarkers of inflammation, sub-clinical markers of atherosclerosis, and increased risk of and/or mortality from cardiovascular Disease (CVD). There remain little information regarding the association between other common Oral inflammatory Disease, systemic inflammation, and CVD. The objective of the study was to assess the association between common Oral Mucosal Diseases, circulating markers of inflammation, and increased prevalence of CVD in a cross-sectional survey of a nationally representative sample of the noninstitutionalized civilians in the United States. Methods Data for this study are from 17,223 men and women aged ≥17 years who received Oral examination as part of the Third National Health and Nutrition Examination Survey. The primary and secondary outcome measures were the association of Oral Mucosal Diseases with raised serum levels of C-reactive protein/fibrinogen and increased prevalence of CVD, respectively. Adjustment for common confounding factors was performed. Results Having Oral Mucosal Disease was associated with systemic inflammation (serum levels of C-reactive protein ≥10 mg/dL) (odds ratio 1.41, 95% CI 1.02-1.94). Individuals with Oral Mucosal Disease were 1.36 times (95% CI 1.02-1.80) more likely to have history of myocardial infarction and 1.33 times (95% CI 1.03-1.71) more likely to report angina than unaffected individuals. All associations were independent of common confounding factors. Conclusions This is the first study to suggest that common Oral Mucosal Diseases are independently associated with raised markers of systemic inflammation and history of CVD.
-
Calcineurin inhibitors in Oral medicine.
Journal of The American Academy of Dermatology, 2009Co-Authors: Khalid A. Al Johani, Stephen Porter, Anne M. Hegarty, S FedeleAbstract:Topically applied calcineurin inhibitors have been suggested to be of some benefit in the treatment of immunologically mediated Oral Mucosal disorders, particularly Oral lichen planus. This article reviews the current evidence of the efficacy and safety of topical calcineurin inhibitor agents in the management of different Oral conditions. Current evidence suggests that topical tacrolimus and pimecrolimus may be of benefit (at least in the short term) in the treatment of immunologically mediated Oral Mucosal Disease, especially Oral lichen planus that has not responded to topical corticosteroids. Both tacrolimus and pimecrolimus are minimally absorbed through the Oral mucosa and give rise to few clinically significant local or systemic adverse side effects. There is little evidence to indicate that topical cyclosporine is more effective than topical corticosteroids for the treatment of immunologically mediated Oral Mucosal Disease. Currently, there is no objective evidence suggesting that topical tacrolimus or pimecrolimus increase the risk of Oral malignancy associated with Oral lichen planus. There is a need for well-designed randomized controlled trials to establish the precise efficacy of topical calcineurin inhibitors for the treatment of immunologically mediated Oral Mucosal Disease.
Richeal Ni Riordain - One of the best experts on this subject based on the ideXlab platform.
-
development and validation of a short version of chronic Oral Mucosal Disease questionnaire comdq 15
Journal of Oral Pathology & Medicine, 2020Co-Authors: Stephen Porter, Paswach Wiriyakijja, S Fedele, T A Hodgson, Roddy Mcmillan, Martina Shephard, Richeal Ni RiordainAbstract:BACKGROUND: The adoption of the Chronic Oral Mucosal Disease Questionnaire (COMDQ) into clinical practice has been low, despite its rigorous development process. A potential limitation of the COMDQ is the high response burden to patients. Therefore, the aim of the present study was to develop and validate a short version of the 26-item COMDQ. METHODS: The COMDQ data of 520 patients with chronic Oral Mucosal Diseases were randomly divided into two subsamples. Descriptive item analysis and exploratory factor analysis (EFA) were performed using data from the first subsample for item reduction and development of the shortened COMDQ. The resulting short version was then validated using confirmatory factor analysis (CFA) on the other subsample. Internal consistency reliability of the short-form COMDQ was assessed using Cronbach's alpha. Criterion validity of this new scale was examined against its original version. RESULTS: Based upon item analysis, 11 items were dropped. EFA results on the remaining 15 items extracted four factors consistent with the original COMDQ, and CFA results displayed acceptable goodness-of-fit indices of this factor structure on different sample. The COMDQ-15 was then created. Cronbach's alpha of four subscale scores ranged from 0.7 to 0.91, indicating good internal consistency reliability of the COMDQ-15. Correlations between total and subscale scores of the COMDQ-15 and its parent scale were high, supporting good criterion validity of this shortened scale. CONCLUSION: The COMDQ-15 is a brief, valid and reliable instrument that can give an overview of the patient's quality of life related to their chronic Oral Mucosal conditions.
-
Development and validation of a short version of Chronic Oral Mucosal Disease Questionnaire (COMDQ‐15)
Journal of Oral Pathology & Medicine, 2019Co-Authors: Paswach Wiriyakijja, Stephen Porter, S Fedele, T A Hodgson, Roddy Mcmillan, Martina Shephard, Richeal Ni RiordainAbstract:BACKGROUND: The adoption of the Chronic Oral Mucosal Disease Questionnaire (COMDQ) into clinical practice has been low, despite its rigorous development process. A potential limitation of the COMDQ is the high response burden to patients. Therefore, the aim of the present study was to develop and validate a short version of the 26-item COMDQ. METHODS: The COMDQ data of 520 patients with chronic Oral Mucosal Diseases were randomly divided into two subsamples. Descriptive item analysis and exploratory factor analysis (EFA) were performed using data from the first subsample for item reduction and development of the shortened COMDQ. The resulting short version was then validated using confirmatory factor analysis (CFA) on the other subsample. Internal consistency reliability of the short-form COMDQ was assessed using Cronbach's alpha. Criterion validity of this new scale was examined against its original version. RESULTS: Based upon item analysis, 11 items were dropped. EFA results on the remaining 15 items extracted four factors consistent with the original COMDQ, and CFA results displayed acceptable goodness-of-fit indices of this factor structure on different sample. The COMDQ-15 was then created. Cronbach's alpha of four subscale scores ranged from 0.7 to 0.91, indicating good internal consistency reliability of the COMDQ-15. Correlations between total and subscale scores of the COMDQ-15 and its parent scale were high, supporting good criterion validity of this shortened scale. CONCLUSION: The COMDQ-15 is a brief, valid and reliable instrument that can give an overview of the patient's quality of life related to their chronic Oral Mucosal conditions.
-
Validity and reliability of the Chronic Oral Mucosal Diseases Questionnaire in a UK population.
Journal of Oral Pathology & Medicine, 2016Co-Authors: Richeal Ni Riordain, Tim Hodgson, Stephen Porter, S FedeleAbstract:OBJECTIVE: The objective of this study was to investigate the validity and reliability of a the Chronic Oral Mucosal Diseases Questionnaire in a UK population METHODS: Two hundred patients with chronic Oral Mucosal Disease (Oral lichen planus, recurrent aphthous stomatitis, mucous membrane pemphigoid, pemphigus vulgaris) were enrolled in this study from the Oral Medicine Department of University College London Hospitals Trust (UCLHT) Eastman Dental Hospital. Individuals were interviewed using Oral Health Impact Profile (OHIP-14), Visual Analogue Scale (VAS) and Chronic Oral Mucosal Diseases Questionnaire (COMDQ), and the construct validity and internal reliability were examined. RESULTS: Of the 200 study participants, 100 respondents had Oral lichen planus, 42 had recurrent aphthous stomatitis and 58 had vesiculobullous conditions (mucous membrane pemphigoid or pemphigus vulgaris). With regard to construct validity, a moderate to good degree of convergent validity was found between OHIP-14 and VAS and most subscales and the total COMDQ score except the patient support subscale of COMDQ (0.21-0.37). CONCLUSION: COMDQ is a valid and reliable patient-reported outcome measure for patients with chronic Oral Mucosal Diseases in a UK population. It can be considered a valuable instrument in both clinical practice and in Oral medicine research.
-
world workshop on Oral medicine vi patient reported outcome measures and Oral Mucosal Disease current status and future direction
Oral Surgery Oral Medicine Oral Pathology and Oral Radiology, 2015Co-Authors: Richeal Ni Riordain, P J Shirlaw, Ivan Alajbeg, Ghada Al Y Zamel, Pok Lam Fung, Anna D Yuan, Christine Mccreary, Eric T Stoopler, Scott S De RossiAbstract:Objective This systematic review aimed to (1) explore the patient-reported outcome measures (PROMs) currently used in the Oral Mucosal Disease literature and report on the type and context of the use of these instruments and (2) provide a future direction for PROMs in Oral Medicine practice and research. Study Design A systematic review of published English-language articles relating to the use of PROMs in the Oral Mucosal Diseases literature was performed in November 2013. Results In total, 131 articles met the inclusion criteria; these articles addressed the following Oral Mucosal conditions: lichen planus (75); recurrent aphthous stomatitis (30); mucous membrane pemphigoid/pemphigus vulgaris (14); orofacial granulomatosis (1); and multiple Oral Mucosal Diseases (11). The most commonly used instruments were visual analog scales (VAS) and the Oral health impact profile (OHIP). Conclusions Limited progress has been achieved with use of PROMs in Oral Medicine in the last few decades in both clinical practice and a research setting. With the engagement of allied medical disciplines in PROM usage and the promotion of PROMs by national health care bodies globally, advancement of PROMs is imperative for Oral Medicine. Exposure through the World Workshop on Oral Medicine (WWOM), along with potential involvement in the Core Outcome Measures in Effectiveness Trials (COMET) or other such initiatives, will enable worldwide collaboration to promote the development and utilization of valid and reliable PROMs in Oral medicine, and improve patient care.
M A Gonzalezmoles - One of the best experts on this subject based on the ideXlab platform.
-
vesiculo erosive Oral Mucosal Disease management with topical corticosteroids 2 protocols monitoring of effects and adverse reactions and the future
Journal of Dental Research, 2005Co-Authors: M A Gonzalezmoles, C ScullyAbstract:Although topical corticosteroids (TCs) are the most widely used drugs in Oral medicine, and specifically in the treatment of vesiculo-erosive Oral Mucosal Disease, there are few evidence-based data for the correct use of these drugs. In this review, we outline the most widely used protocols, the most common reasons for treatment failure, and the adverse effects documented in the literature.
-
vesiculo erosive Oral Mucosal Disease management with topical corticosteroids 1 fundamental principles and specific agents available
Journal of Dental Research, 2005Co-Authors: M A Gonzalezmoles, Crispian ScullyAbstract:Vesiculo-erosive Diseases of the Oral mucosa pose a major challenge in Oral medicine, because they are chronic, painful, and interfere with the daily activities and quality of life of the patients, including disturbing eating, drinking, talking, and personal relationships. Many are autoimmune Diseases, and corticosteroid therapy is currently central to their treatment. These Diseases present with inflammation and alterations to epithelial integrity, through cell and/or humOral immunity-mediated attack on epithelial-connective tissue targets. Until recently, despite their serious adverse effects, it was necessary to prescribe systemic corticosteroids to control severe erosive Oral Diseases. Now, however, many of these Diseases can be controlled by high-potency topical corticosteroids, which have proved to be highly efficacious and to cause fewer adverse effects compared with systemic corticosteroids. Nevertheless, although topical corticosteroids are still the most widely used drugs in the practice of Oral medicine, the scientific body of evidence for their use in the Oral cavity is virtually non-existent, and therefore many of the protocols followed are, of necessity, drawn from experience of their use in a dermatological setting. This review aims to set out the key aspects of the use of topical corticosteroids in Oral medicine. The issues covered include the indications and basic rules for their use, the types of corticosteroids, the drug selection, and the specific formulations.